RAUVAL
Clinical safety rating
cautionComprehensive clinical and safety monograph for RAUVAL (RAUVAL).
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
| Metabolism | Metabolized in the liver via CYP450 enzymes, primarily CYP3A4, to active and inactive metabolites. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%. |
| Half-life | Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment. |
| Protein binding | 85-90% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.6-1.0 L/kg; indicates extensive extravascular distribution. |
| Bioavailability | Oral: 60-70% due to first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 8-12 hours; Intravenous: 4-8 hours; clinical effects correlate with plasma levels. |
| Molecular Weight | 390.47 |
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min. For GFR <30 mL/min, dose reduction by 50% is recommended. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; maximum 1.5 mg daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients under 18 years. |
| Geriatric use | Start at 1 mg orally once daily; consider slower titration due to increased sensitivity to orthostatic hypotension. |
| 1st trimester | Avoid: Teratogenic effects observed in animal studies; limited human data but risk of congenital anomalies cannot be excluded. |
| 2nd trimester | Caution: May cause fetal harm; consider risk-benefit. No adequate human studies. |
| 3rd trimester | Avoid: Risk of neonatal adverse effects including respiratory depression and withdrawal. |
Clinical note
Comprehensive clinical and safety monograph for RAUVAL (RAUVAL).
| Placental transfer | High: Demonstrated placental transfer in animal models; human data suggest extensive crossing. |
| Breastfeeding | Not recommended: Excreted in breast milk; potential for serious adverse reactions in nursing infants. Discontinue drug or nursing. |
| Lactation Rating | L5 |
| Teratogenic Risk | First trimester: Increased risk of cardiovascular malformations. Second and third trimesters: Associated with fetal growth restriction, oligohydramnios, and neonatal renal impairment. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound. Assess amniotic fluid volume regularly. |
| Fertility Effects | Rauval may cause reversible infertility in females due to anovulation and in males due to impaired spermatogenesis. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to RAUVALAcute angle-closure glaucomaSevere hepatic impairment
| Precautions | May cause mental depression, especially at high doses, and should be discontinued if signs of depression appear., Use with caution in patients with a history of peptic ulcer disease as it increases gastric acid secretion., May cause orthostatic hypotension, tachycardia, and electrolyte disturbances., Abrupt discontinuation may lead to withdrawal symptoms such as agitation, anxiety, and hypertension. |
| Food/Dietary | Avoid tyramine-rich foods (aged cheeses, cured meats, fermented products) as rauwolfia may potentiate pressor effects. Limit salt intake to support blood pressure control. Grapefruit juice may increase drug levels; avoid concurrent consumption. |
| Clinical Pearls | Rauval (rauwolfia alkaloids) is an antihypertensive that depletes catecholamines. Avoid in patients with history of depression or peptic ulcer disease. Onset is slow (weeks), so not for hypertensive emergencies. Monitor for orthostatic hypotension, especially at initiation. May cause nasal congestion and bradycardia. Discontinue at least 2 weeks before elective surgery to avoid anesthetic interactions. |
| Patient Advice | Take exactly as prescribed; do not stop abruptly as it may cause rapid blood pressure increase. · Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or drowsiness. · Rise slowly from sitting or lying down to prevent falls due to low blood pressure. · Report any signs of depression, slow heartbeat, or unusual bruising/bleeding to your doctor. · Avoid alcohol, as it may worsen dizziness and drowsiness. |
Loading safety data…